[The trend in the development of the active vitamin D3 and its analogues].
Miwa
Naoko
N
Department of Medicine, Kidney Center, Tokyo Women's Medical University.
Akiba
Takashi
T
D002117:Calcitriol / Q000031:analogs & derivatives*; D002762:Cholecalciferol / Q000031:analogs & derivatives / Q000627:therapeutic use; D015195:Drug Design; D004872:Ergocalciferols; D006801:Humans; D006887:Hydroxycholecalciferols; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications; D014807:Vitamin D / Q000031:analogs & derivatives; D005466:Fluorocarbons
D002117:Calcitriol; D002762:Cholecalciferol; D004872:Ergocalciferols; D006887:Hydroxycholecalciferols; D014807:Vitamin D; C042533:1 alpha-hydroxyergocalciferol; C084656:paricalcitol; C040488:26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3; D005466:Fluorocarbons; C547512:eldecalcitol; C051883:maxacalcitol; C008088:alfacalcidol